-
6 days ago | 
360dx.com | Kelsy Ketchum
NEW YORK – Although it had multiple products with regulatory clearance and technology that had been validated by outside users, Accelerate Diagnostics' inability to attract buyers for its instruments doomed the company. On Thursday the Tucson, Arizona-based developer of antibiotic susceptibility testing platforms and assay filed for Chapter 11 bankruptcy protection in the US Bankruptcy Court for the District of Delaware.
-
1 week ago | 
360dx.com | Kelsy Ketchum
Note: This story has been updated with comments from the conference call to discuss the firm's financial results. NEW YORK – Despite macroeconomic uncertainty related to tariffs announced by President Donald Trump last month, Bio-Techne executives said the company is well positioned to mitigate the impact of tariffs by the end of fiscal 2025.
-
1 week ago | 
genomeweb.com | Kelsy Ketchum
Note: This story has been updated with comments from the conference call to discuss the firm's financial results. NEW YORK – Despite macroeconomic uncertainty related to tariffs announced by President Trump last month, Bio-Techne executives said the company is well positioned to mitigate the impact of tariffs by the end of fiscal 2025.
-
1 week ago | 
360dx.com | Kelsy Ketchum
Note: This story has been updated with comments from the conference call to discuss the firm's financial results. NEW YORK – Despite macroeconomic uncertainty related to tariffs announced by President Trump last month, Bio-Techne executives said the company is well positioned to mitigate the impact of tariffs by the end of fiscal 2025.
-
1 week ago | 
360dx.com | Kelsy Ketchum
NEW YORK – Kiffik Biomedical and Rubix LS are working together to combine an interstitial fluid collection device and aptamer biosensing for rapid, at-home, cancer detection at the point of care. Without using traditional sample types like blood or saliva, the companies hope to use their new technology to deliver "real-time, needle-free insights," said Deb Ruppert, Kiffik's head of global marketing.
-
1 week ago | 
genomeweb.com | Kelsy Ketchum
NEW YORK – Tempus AI on Tuesday announced that its Q1 2025 revenues rose 75 percent year over year. Chicago-based Tempus reported revenues of $255.7 million for the quarter ended March 31, up from $145.8 million in Q1 2024 and beating the Wall Street consensus estimate of $248.1 million.
-
2 weeks ago | 
genomeweb.com | Kelsy Ketchum
NEW YORK – Uppsala University spinout Readily Diagnostics is using technology built off 30 years of research as the basis of a point-of-care, instrument-free test that would detect and differentiate between multiple respiratory diseases. The Swedish firm is using padlock probes, which involve a DNA molecule hybridizing and finding a target in a sample, but has added a proprietary twist to speed up the reaction time, Readily Diagnostics CEO Liza Löf said in an interview.
-
3 weeks ago | 
360dx.com | Kelsy Ketchum
Note: This story has been updated with comments from Roche's conference call to discuss its financial results. NEW YORK – Impacts from China's volume-based procurement program and other healthcare pricing reforms led to flat Q1 diagnostics revenues year over year for Roche, company executives said Thursday. Roche reported its diagnostics sales in the first quarter of 2025 came in at CHF 3.49 billion ($4.23 billion).
-
3 weeks ago | 
360dx.com | Kelsy Ketchum
Note: This story has been updated with comments from a conference call discussing the firm's financial results. NEW YORK – Although Danaher is prepared for an impact of approximately $350 million related to the tariffs that have been put in place by President Trump throughout 2025, company executives said on a conference call to discuss the firm's financial results Tuesday that they have a "number of levers" that they can deploy to account for the headwinds.
-
4 weeks ago | 
360dx.com | Kelsy Ketchum
VIENNA – Following last week's announcement by Cepheid and Oxford Nanopore Technologies to partner on automated nanopore sequencing workflows for infectious diseases, the firms provided more details on their upcoming plans on the sidelines the European Society of Clinical Microbiology and Infectious Diseases global congress here this week.
